Im Fokus: Glukosehomöostase bei Typ-2-Diabetes ... - Medscape

51. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin,
an Inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), Improves
Glycemic Control and Lowers Body Weight in Subjects with Type 2
Diabetes (T2D) on Metformin. 70th American Diabetes Association
Scientific Sessions. 2010. 77-OR.
52. Johnson & Johnson Pharmaceutical Research and Development. Phase III
clinical trials with canagliflozin. http://clinicaltrials.gov/ct2/results?term=
canagliflozin.2011. ;Available at: URL: http://clinicaltrials.gov/ct2/results?te
rm=canagliflozin&recr=&rslt=&type=&cond=&intr=&outc=&lead=&spo
ns= &id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=
&gndr=&phase=2&rcv_s=&rcv_e=&lup_s=&lup_e=. (Accessed 04
December 2011).
53. Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet.
2010;375(9733):2196-2198.
53. Bristol-Myers Squibb and AstraZeneca. Meta-Analysis of Clinical Data on
Cardiovascular Safety Presented for Investigational Compound
Dapagliflozin in Adult Patients with Type 2 Diabetes. http://www.bms.
com/
news/press_releases/pages/default.aspx. (Accessed 04 December 2011).
55. AstraZeneca Global. Bristol Myers Squibb and AstraZeneca announce
investigational compound DAPAGLIFLOZIN sustained glycemic control
and weight reduction in study of Type2 Diabetes patients inadequately
controlled with metformin. http://www.astrazeneca.com/Media/
Press-releases/Article/bristol-myers-squibb-and-astrazeneca-ph3-
study-on-dapaglifozin. 2011. (Accessed 04 December 2011).
56. Seman L, Rosenstock J, Jelaska A, Pinnetti S, Hantel S, Woerle HJ. ENCORE:
efficacy and safety of BI 10773, a new sodium glucose cotransporter-2
(SGLT-2) inhibitor, in type 2 diabetes patients inadequately controlled on
metformin. Diabetologia. 2911;54 (Suppl 1). 147
www.medscape.org/clinical-update/t2dm
57. Boehringer Ingelheim Pharmaceuticals. BI 10773 (empagliflozin) Phase III
clinical trials. http://clinicaltrials.gov/ct2/results?term=BI+10773&recr=&rs
lt=&type=&cond=&intr=&outc=&lead=&spons=&id=&state1=&cntry1=
&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=2&rcv_
s=&rcv_e=&lup_s=&lup_e=. 2011. (Accessed 04 December 2011).
58. Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I. Ipra
gliflozin improved glycaemic control with additional benefits of
reductions of body weight and blood pressure in Japanese patients with
type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia 2011;54
(Suppl 1). 149.
59. Astellas Pharma Inc. Ipragliflozin clinical trials. http://clinicaltrials.gov/ct2/
results?term=ipragliflozin. 2011. (Accessed 04 December 2011).
60. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. A novel
potent and highly selective renal sodium-glucose co-transporter 2 (SGLT2)
inhibitor, TS-071, improves glycaemic control and lowers body weight in
Japanese patients with type 2 diabetes mellitus. Diabetologia; 2011;54
(Suppl 1). 148.
61. Lexicon Pharmaceuticals. LX4211 clinical trials. http://clinicaltrials.gov/ct2/
results?term=LX4211&recr=&rslt=&type=&cond=&intr=&outc=&lead=&sp
ons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&
gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=. 2011. (Accessed 04 December
2011).
62. Dobbins RL, O’Connor-Semmes R, Kapur A et al. Remogliflozin etabonate,
a selective inhibitor of the sodium-dependent transporter 2 reduces se
rum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab.
2011. doi:10.1111/j.1463-1326.2011.01462.x [epub ahead of print]
63. Pfizer. PF04971729 clinical trials. http://clinicaltrials.gov/ct2/
results?term=PF04971729. 2011. (Accessed 04 December 2011).
64. Powell D, Freiman J, Frazier K et al. Single doses of LX4211, a dual inhibitor
of SGLT1 and SGLT2, improves parameters of glycaemic control and
increases GLP-1 and PYY in patients with type 2 diabetes. Diabetologia,
2011;54 (Suppl 1). 150.
Unterstützt durch unabhängige Fortbildungsförderung von
Bristol-Myers Squibb Company und AstraZeneca.
Pg.21